Literature DB >> 104329

Lithium prevention of amphetamine-induced 'manic' excitement and of reserpine-induced 'depression' in mice: possible role of 2-phenylethylamine.

R L Borison, H C Sabelli, P J Maple, H S Havdala, B I Diamond.   

Abstract

Repeated treatment of mice with lithium chloride (45 mg/kg, i.p., daily for 8 days) reduced the jumping, fighting, stereotypies, and hyperactivity induced by d-amphetamine (5 mg/kg, i.p.). Lithium also reduced the hypoactivity observed 1--3 h after reserpine (0.75 mg/kg, i.p.). In biochemical studies we found that 8-day treatment with lithium markedly reduced (to 45% of control) the recovery from brain of labelled 2-phenylethylamine (PEA) following i.p. injection of labelled L-phenylalanine, while decreasing recovery from brain of labelled PEA following its i.p. injection of 63% of control. In saline-treated mice, d-amphetamine appeared to increase PEA synthesis and to accelerate its disposition, whereas reserpine enhanced PEA synthesis and reduced disposition; all of these effects were antagonized by lithium pretreatments. Since PEA appears to be one of the most powerful behavioral stimulants among endogenous neuroamines, and because its deaminated metabolites are behavioral depressants, such antagonism of brain PEA metabolism may significantly contribute to the prophylactic action of lithium against both manic and depressive behavior.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 104329     DOI: 10.1007/bf00426631

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  10 in total

1.  Brain 2-phenylethylamine as a major mediator for the central actions of amphetamine and methylphenidate.

Authors:  R L Borison; A D Mosnaim; H C Sabelli
Journal:  Life Sci       Date:  1975-10-15       Impact factor: 5.037

2.  Evidence for the biological activity of the deaminated metabolites of the adrenergic amines.

Authors:  W J Giardina; H C Sabelli
Journal:  Biol Psychiatry       Date:  1974-08       Impact factor: 13.382

3.  Phenylethylamine hypothesis of affective behavior.

Authors:  H C Sabelli; A D Mosnaim
Journal:  Am J Psychiatry       Date:  1974-06       Impact factor: 18.112

4.  The influence of psychotropic drugs on the levels of endogenous 2-phenylethylamine in rabbit brain.

Authors:  A D Mosnaim; E E Inwang; H C Sabelli
Journal:  Biol Psychiatry       Date:  1974-04       Impact factor: 13.382

5.  Phenethylamine content of human urine and rat brain, its alterations in pathological conditions and after drug administration.

Authors:  E Fischer; H Spatz; B Heller; H Reggiani
Journal:  Experientia       Date:  1972-03-15

6.  Effects of lithium and of pH on synaptosomal metabolism of noradrenaline.

Authors:  R J Baldessarini; C Yorke
Journal:  Nature       Date:  1970-12-26       Impact factor: 49.962

Review 7.  Overview: maintenance therapy in psychiatry: II. Affective disorders.

Authors:  J M Davis
Journal:  Am J Psychiatry       Date:  1976-01       Impact factor: 18.112

8.  Biosynthesis of brain 2-phenylethylamine: influence of decarboxylase inhibitors and D-amphetamine.

Authors:  R L Borison; A D Mosnaim; H C Sabelli
Journal:  Life Sci       Date:  1974-11-15       Impact factor: 5.037

9.  The antagonism of phenylethylamine to catecholamines on mouse motor activity.

Authors:  E Fischer; R I Ludmer; H C Sabelli
Journal:  Acta Physiol Lat Am       Date:  1967

10.  Therapy of depression by phenylalanine. Preliminary note.

Authors:  E Fischer; B Heller; M Nachon; H Spatz
Journal:  Arzneimittelforschung       Date:  1975-01
  10 in total
  13 in total

1.  Antipsychotic-like effects of a neurotensin receptor type 1 agonist.

Authors:  Chelsea A Vadnie; Jennifer Ayers-Ringler; Alfredo Oliveros; Osama A Abulseoud; Sun Choi; Mario J Hitschfeld; Doo-Sup Choi
Journal:  Behav Brain Res       Date:  2016-02-22       Impact factor: 3.332

2.  Behavioral effects of bidirectional modulators of brain monoamines reserpine and d-amphetamine in zebrafish.

Authors:  Evan Kyzar; Adam Michael Stewart; Samuel Landsman; Christopher Collins; Michael Gebhardt; Kyle Robinson; Allan V Kalueff
Journal:  Brain Res       Date:  2013-07-01       Impact factor: 3.252

3.  Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome.

Authors:  Zhong-Hua Liu; De-Maw Chuang; Carolyn Beebe Smith
Journal:  Int J Neuropsychopharmacol       Date:  2010-05-25       Impact factor: 5.176

Review 4.  Lithium: a promising treatment for fragile X syndrome.

Authors:  Zhonghua Liu; Carolyn Beebe Smith
Journal:  ACS Chem Neurosci       Date:  2014-05-15       Impact factor: 4.418

Review 5.  Reverse translational strategies for developing animal models of bipolar disorder.

Authors:  Oz Malkesman; Daniel R Austin; Guang Chen; Husseini K Manji
Journal:  Dis Model Mech       Date:  2009 May-Jun       Impact factor: 5.758

6.  Effects of lithium on behaviour induced by phencyclidine and amphetamine in rats.

Authors:  R G Fessler; R D Sturgeon; S F London; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

Review 7.  The behavioral actions of lithium in rodent models: leads to develop novel therapeutics.

Authors:  Kelley C O'Donnell; Todd D Gould
Journal:  Neurosci Biobehav Rev       Date:  2007-04-13       Impact factor: 8.989

8.  Chronic lithium treatment rectifies maladaptive dopamine release in the nucleus accumbens.

Authors:  Adem Can; Douglas O Frost; Roger Cachope; Joseph F Cheer; Todd D Gould
Journal:  J Neurochem       Date:  2016-10-18       Impact factor: 5.372

9.  Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia.

Authors:  D P van Kammen; J P Docherty; S R Marder; J E Rosenblatt; W E Bunney
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Strain-specific battery of tests for domains of mania: effects of valproate, lithium and imipramine.

Authors:  Shlomit Flaisher-Grinberg; Haim Einat
Journal:  Front Psychiatry       Date:  2010-04-22       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.